Celladon's Advanced Heart Failure Treatment Fails In Mid-Stage Study By: TalkMarkets April 27, 2015 at 11:53 AM EDT Shares of Celladon are down 70% after announcing that Mydicar failed to produce significant results in advanced heart-failure patients. Read More >> Related Stocks: Bluebird Bio Spark Therap Uniqure Ord Shs